Cancer News
OncoLink Cancer News - HealthDay

Combination of immune stimulants and regulatory molecules blocks angiogenesis

Thursday, December 16, 2010 (Last Updated: 12/17/2010)

THURSDAY, Dec. 16 (HealthDay News) -- A combination therapy of immune stimulants and regulatory molecules appears to block angiogenesis critical to tumor development, according to research published in the Dec. 15 issue of Cancer Research.

Jonathan Schoenfeld, M.D., of Harvard Medical School in Boston, and colleagues analyzed tumor and blood samples from patients who had responded to a combination treatment of immune stimulants and regulatory molecules.

The researchers found that the combination therapy stimulated a host response that inhibited tumor blood vessels. The patients' antibodies to angiopoietin-1 and angiopoietin-2 blocked Tie-2 binding, downstream signaling, endothelial cell tube formation, and macrophage chemotaxis, while antibodies to macrophage inhibitory factor attenuated matrix metalloproteinase-9 production and macrophage Tie-2 expression.

"Together, these results delineate an immunotherapy-induced host response that broadly targets the angiogenic network in the tumor microenvironment," the authors write.

Full Text (subscription or payment may be required)

Specialties Hematology & Oncology

Copyright © 2010 HealthDay. All rights reserved.

I Wish You Knew

How an oncology social worker can improve your cancer experience

View More

Blogs and Web Chats

OncoLink Blogs give our readers a chance to react to and comment on key cancer news topics and provides a forum for OncoLink Experts and readers to share opinions and learn from each other.

OncoLink OncoPilot

Facing a new cancer diagnosis or changing the course of your current treatment? Let our cancer nurses help you through!

Learn More